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Health-related quality of life (QOL) has become an important topic in health care. However, hardly any attention 
has been paid to QOL in sarcoidosis. Therefore, the aim of this study was to assess the impact of sarcoidosis on 
QOL. Sixty-four sarcoidosis patients completed the World Health Organization Quality of Life assessment 
instrument (WHOQOL-100) and the Beck Depression Inventory (BDI). For the WHOQOL-100 a matched group of 
healthy controls was selected. Patients were divided into two groups: group I (n=37) consisted of patients with actual 
symptoms, group II (n=27) consisted of asymptomatic patients. The WHOQOL-100 revealed a number of areas in 
which sarcoidosis patients, especially those with current symptoms, experienced problems. A major symptom in both 
groups of sarcoidosis patients was fatigue. No association between the facet fatigue and the domain psychological 
health was found. Depressive symptoms (BDI) were associated with psychological function (WHOQOL-100). No 
association between pulmonary function tests and QOL was found. In conclusion, this study shows that sarcoidosis 
has a considerable impact on the QOL of patients. The WHOQOL-100 appeared to be a sensitive instrument to 
measure fatigue-one of the most common symptoms in sarcoidosis -which otherwise is difficult to assess 
objectively. 
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Introduction 
Over the past two decades, health status and quality of life 
(QOL) have been studied for a considerable number of 
chronic disease conditions (1) including respiratory diseases 
such as asthma (2) and chronic obstructive pulmonary 
disease (COPD) (3-9). COPD has been associated with 
impaired QOL (4,6), a high incidence of depression (3,5,6) 
and anxiety (6). However, the relationship between the 
physiological parameters of severity of COPD and QOL, 
when present, is not strong (7-9). 
With respect to sarcoidosis, no studies regarding health 
status or QOL were found. Depending on the severity of 
sarcoidosis and the organ systems involved, patients are 
asymptomatic or present with symptoms such as cough, 
dyspnoea, chest pain, skin lesions and joint and muscle 
pain. The wide spectrum of symptoms makes sarcoidosis 
only partly comparable with other chronic respiratory 
disorders like COPD. The greatest impact on QOL in 
sarcoidosis, as seen in the clinical practice, seems to be 
caused by symptoms such as fatigue and sleeping dis- 
orders. Fatigue is a common problem in many chronic 
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disorders (10). Furthermore, fatigue and sleeping disorders 
are often associated with depression. With respect to 
depression in sarcoidosis, research by Klonoff and 
Kleinhenz suggests that sarcoidosis patients as a group do 
not meet the criteria for clinical depression. Awareness of 
bodily sensations, however, was found to be associated with 
more depressive symptoms and avoidance of activities when 
alone (11). 
In sarcoidosis, QOL and the feature fatigue have not 
been studied. Therefore, the primary objective of this study 
was to evaluate the QOL of sarcoidosis patients. A broad- 
ranging QOL instrument, the WHOQOL-100, which also 
measures fatigue, was employed. A secondary objective of 
this study was to investigate whether fatigue and sleeping 
problems in sarcoidosis patients are related to depressive 
symptoms. 
Methods 
PATIENTS 
The patients suffering from sarcoidosis from eight partici- 
pating Dutch hospitals (Rijnstate Hospital, Arnhem; 
Academic Hospital St Radboud, Nijmegen; Rehabilitation 
Centre Dekkerswald, Nijmegen; District Hospital Middle 
Twente, Hengelo; St. Jans-Hospital, Weert; Maasland 
Hospital, Sittard; The Wever Hospital, Heerlen; and 
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TABLE 1. Demographic characteristics of the studied sarcoidosis patients with separate data for 
patients with (group I) and without (group II) current symptoms and the control group 
Sarcoidosis patients Control group 
Number of cases 
Gender (male/female) 
Age* 
Smoking (yes/no) 
Total group 
64 
37127 
42.7 * 11.9 
1 l/53 
Group I 
37 
21/16 
45.4 f 12.8 
8129 
Group II 
21 
16/11 
39.0 & 9.6 
3124 
64 
37127 
42.8 I!C 12 
*Data are expressed in mean * SD. 
University Hospital, Maastricht) were studied. The diagno- 
sis of sarcoidosis was based on consistent clinical features, 
along with biopsy evidence of noncaseating epitheloid cell 
granulomas. The clinical symptoms of the respective 
patients varied from none (sarcoidosis detected on routine 
chest X-ray film) to respiratory and general constitutional 
symptoms or erythema nodosum and arthralgia (i.e. 
Liifgren’s syndrome). None of the participating subjects 
had any medical history, which might influence the quality 
of life. Moreover, patients with co-morbidity were 
excluded. None of the patients had any anti-depressant 
pharmacotherapy. In order to be able to evaluate the 
possible impact of the reported symptoms, as well as to 
evaluate the quality of life in patients without reported 
symptoms, the patients were divided into two groups and 
were studied separately. Group I consisted of patients with 
current symptoms (n=37), whereas group II consisted 
of the patients without current symptoms (n=27). The 
mean (SD) time from diagnosis for the whole group of 
sarcoidosis patients was 5.0 (5.5) years. For demographic 
characteristics of the patients see Table 1. 
PROCEDURE 
Seventy-one sarcoidosis patients from the eight participat- 
ing hospitals were contacted. Seven patients declined for 
various private reasons, but 64 patients agreed to partici- 
pate after signing an informed consent. These sarcoidosis 
patients were studied. They completed the WHOQOL-100 
and the Beck Depression Inventory (BDI). In addition, the 
physician asked patients about their smoking habits and 
whether they had any of the following symptoms: fatigue, 
dyspnoea, cough, arthralgia and/or erythema nodosum. 
The values of the assessed pulmonary function tests were 
obtained from the patient record, from the visit closest to 
the session the questionnaires were completed. 
The healthy control group was recruited in the following 
way: 528 persons selected at random from the zipcode book 
were called. Of these persons 240 indicted to be willing to 
participate in a study on QOL. From the group of persons 
who returned a completed test-booklet (n= 178; 74.2%) 
matched healthy control subjects (n=64) were selected on 
the basis of gender and age (Table 1). These control persons 
were used in order to compare their WHOQOL-100 scores 
with those of the sarcoidosis patients; they did not complete 
the Beck Depression Inventory (BDI). The control group 
was divided into two groups in such a way that patients 
with and without current symptoms had their own matched 
control group. The rationale for splitting the control group 
was that both groups of sarcoidosis patients would have 
their own matched controls in case the results showed that 
patients with current symptoms scored significantly 
different with respect to QOL from the patients without 
current symptoms. 
Both questionnaires, the WHOQOL-100 and the BDI are 
self-report measures. After the subjects had completed 
these questionnaires, a study assistant checked whether 
the questionnaires had been filled in completely and no 
questions were skipped. 
PULMONARY FUNCTION TESTS 
Pulmonary function measurements included the forced 
expiration volume in 1 s (FEV,) (Compactbody, Jaeger, 
Wtirzburg, Germany). The best measure of three efforts was 
selected. All volumes are expressed as percentages of the 
reference values (12). The diffusing capacity for carbon 
monoxide (DLCO) was measured using the single breath 
method (Masterlab, Jaeger, Wtirzburg, Germany). 
Modifications in FEV, and DLCO 
In order to compare the FEV, and DLCO levels with the 
quality of life scores, the values were classified according 
to the American Medical Association classes: (1) normal 
range (~80%); (2) mild decrease (60-80%); (3) moderate de- 
crease (40-60%) and (4) severe decrease (~40%) predicted, 
respectively. 
QUESTIONNAIRES 
World Health Organization Quality of Life assessment 
instrument (WHOQOL-100) 
The WHOQOL-100 (Dutch version) (13) is a cross- 
culturally developed generic multidimensional QOL 
measure that has been simultaneously developed in 15 
centres around the world, such as in France, Russia, the 
U.S.A., Panama, Zimbabwe, Japan, Thailand, and The 
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TABLE 2. WHOQOL items from the facets energy and fatigue and sleep and rest from the domain 
physical health 
Facet ‘energy and fatigue’ How easily do you get tired? 
How much are you bothered by fatigue? 
Do you have enough energy for everyday life? 
How satisfied are you with the energy you have? 
Facet ‘sleep and rest’ Do you have any difficulties sleeping? 
How much do any sleep problems worry you? 
How satisfied are you with your sleep? 
How well do you sleep? 
Netherlands (14). The World Health Organization Quality 
of Life group (WHOQOL group) has defined QOL as ‘an 
individual’s perception of his/her position in life in the 
context of the culture and value systems in which he/she 
lives and in relation to their goals, expectations, standards, 
and concerns’ (14). 
The WHOQOL-100 consists of 100 items assessing 24 
facets of QOL within six domains (physical health, psycho- 
logical health, level of independence, social relationships, 
environment, and spirituality/religion/personal beliefs) and 
a general evaluative facet (overall quality of life and general 
health). Table 2 gives the questions from the facets energy 
and fatigue and sleep and rest from the domain physical 
health. Each facet is represented by four items. The 
response scale is a five-point Likert scale (14). Except for 
the facets pain and discomfort, negative feelings, and 
dependence on medication or treatments, higher scores 
show a better QOL for the facet or domain. Before calcu- 
lating the domain scores the scores of these three facets 
have to be reversed. The reliability and validity of the 
Dutch version of the WHOQOL are high (15). For 
instance, the Cronbach alphas for the separate facets 
range from 0.71 to 0.94 and the questionnaire makes clear 
distinctions between healthy and chronically ill subjects. 
Beck Depression Inventory (BDI) 
Depressive symptoms of the sarcoidosis patients were 
measured with the BDI (16). This instrument consists of 
statements which are grouped in 21 groups of four possible 
responses. Each answer is scored on a four-point Likert- 
type scale of O-3. In previous studies internal consistency 
was mostly higher than 0.85. Bosscher et al. found scores 
ranging from 4.5 to 5.0 in a non-clinical student population 
(17). A patient with a total score of 15 or above was 
considered to have significant depressive symptoms (5). In 
order to control for the physical effects of the ilhless on 
mood, items referring to problems with fatigue, sleep, 
sexual dysfunction, eating, weight, and general health were 
summed and labelled the physical depression index (PDI). 
The remaining items were summed and labelled the cogni- 
tive depression index (CDI). Peterson et al. showed that this 
was a valid way of preventing spurious relationships in a 
population with end-stage renal disease (18). Internal 
consistency of the CD1 in this sample was high (n=0.85). 
STATISTICS 
Data are expressed as mean & SD and, if appropriate, as a 
mean with its range. In order to detect statistically signifi- 
cant differences between the patient groups and their con- 
trol groups, data were analysed for the WHOQOL-100 with 
Student’s t-tests. 
The significance concerning personal characteristics was 
tested using x2 tests for categorical data and Student’s 
t-tests for continuous data. Due to the number of facets in 
the WHOQOL-100 and thus the number of analyses exam- 
ined, a probability value of less than 0.01 was considered to 
be statistically significant. All analyses were performed 
using the Statistical Package for the Social Sciences (SPSS) 
(1% 
Results 
Patients with current symptoms (n=37; group I) had also 
had more symptoms at the time of the initial presentation 
of sarcoidosis than those without current symptoms (n=27; 
group II). 
The reported actual symptoms of the group of sympto- 
matic patients were fatigue in 28 cases, dyspnoea in 15 
cases, arthralgia in 11 cases, cough in six cases, and 
erythema nodosum in one. In line with this, the major 
symptom assessed by the WHOQOL-100 domain physical 
health also appeared to be fatigue. 
The QOL of the patients suffering from sarcoidosis was 
scrutinized for the WHOQOL-100 domains and their 
facets, separately. Age was related to lower scores on the 
facet transport (r=0.37, P<O.Ol) and higher scores on the 
facet dependence on medication or treatments (rz0.34, 
PCO~Ol). 
Symptomatic patients (n = 37) scored significantly differ- 
ent from the asymptomatic patients with respect to the 
domain level of independence (equal variance t-value 4.28, 
P~O.001) and the facets mobility (equal variance t-value 
3.15, P<O.Ol), activities of daily living (equal variance 
t-value 3.88, P<O.Ol), dependence on medication or treat- 
ments (equal variance t-value - 3.29, P<O.Ol), working 
capacity (unequal variance t-value 4.55, P<O.Ol), positive 
feelings (equal variance t-value 2.79, P<O.Ol), and partici- 
pating in and possibilities for recreation/leisure (equal 
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TABLE 3. WHOQOL-100 scores of the studied sarcoidosis patients with separate data for the patients 
with (group I) and without (group II) current symptoms and the scores for the total control group 
WHOQOL- 100 scores 
Group I Group II Control group 
(n=37) (n=27) (n=64) 
Overall Quality of Life and General Health 14.2 (3.7) 14.2 (3.7) 
Physical health 14.3 (2.8) 14.2 (3.4) 
Pain and discomfort 9.2 (3.1) 9.1 (3.8) 
Energy and fatigue 12.2 (3.7) 12.0 (4.5) 
Sleep and rest 14.8 (38) 16.9 (3.6) 
Psychological health 14.5 (2.6) 16.1 (2.0) 
Positive feelings? 13.8 (3.0) 15.7 (2.2) 
Thinking, learning, memory, and concentration 14.0 (3.4) 16.1 (2.9) 
Self-esteem 13.9 (3.0) 15.2 (2.4) 
Body image and appearance 16.1 (35) 17.2 (2.2) 
Negative feelings 9.1 (3.1) 7.8 (3.0) 
Level of independence* 13.9 (3.3) 17.2 (2.7) 
Mobility? 15.5 (3.4) 18.0 (2.4) 
Activities of daily living? 13.4 (3.7) 16.8 (3.3) 
Dependence on medication and treatments? 10.0 (4.2) 6.8 (3.2) 
Working capacity? 128 (4.2) 17.0 (3.3) 
Social relationships 15.4 (2.8) 16.9 (2.5) 
Personal relationships 15.7 (3.0) 17.1 (2.8) 
Social support 15.4 (3.6) 17.2 (2.8) 
Sexual activity 15.2 (3.3) 16.3 (2.9) 
Environment 15.6 (2.1) 16.9 (1.9) 
Physical safety and security 15.7 (2.8) 16.9 (2.8) 
Home environment 15.5 (2.9) 17.2 (2.9) 
Financial resources 16.5 (3.2) 17.3 (2.3) 
Health and social care: availability and quality 15.1 (2.1) 16.0 (2.7) 
Ability to acquire new information and skills 15.5 (2.8) 16.3 (2.5) 
Participating in and possibilities for recreation/leisure+ 14.3 (3.8) 16.8 (2.9) 
Physical environment (pollution/noise/traffic/climate) 14.7 (28) 15.6 (2.6) 
Transport 17.3 (3.4) 18.9 (1.7) 
Spirituality/religion/personal beliefs 12.8 (3.5) 13.7 (3.4) 
16.0 (2.5)s 
16.0 (1.9)$ 
9.0 (2.9) 
15.3 (2.5)f 
17.6 (2.4)§ 
15.3 (1.7) 
14.6 (1.8) 
14.8 (2.3) 
14.7 (2.0 
17.0 (2.5) 
8.6 (2.9) 
17.4 (2.4) 
17.3 (3.2) 
17.0 (2.3) 
5.8 (2.9) 
17.3 (2.8) 
15.6 (2.2) 
16.1 (2.0 
15.8 (2.4) 
14.6 (3.1) 
15.6 (1.7) 
15.5 (2.0) 
15.6 (2.6) 
15.7 (3.1) 
14.8 (2.2) 
15.5 (2.4) 
15.7 (2.7) 
14.9 (2.2) 
17.3 (3.0) 
12.7 (2.7) 
Note: Student’s t-tests were applied. Data are expressed as mean with SD in parentheses. Group I vs 
group II: *P<O.OOl, tP<O.Ol. Total patient group (scores not shown) VS. total control group: 
$PiO.OOl, §PCO.Ol. 
variance t-value 2.82, PcO.01). In each case, the QOL of the 
patients with symptoms was lower than the QOL of the 
patients without symptoms (Table 3). 
For these domains and facets, separate analyses were 
done for patients with symptoms and matched healthy 
control subjects, and patients without symptoms and their 
matched healthy control subjects, respectively. 
Regarding the domain level of independence, the symp- 
tomatic patients scored lower (unequal variance t-value 
5.24, df 64.4, P<O.OOl) than their control group. At facet 
level, these patients scored lower on activities of daily living 
(unequal variance t-value 5.43, df 59, P<O.OOl), and work- 
ing capacity (unequal variance t-value 5.04, df 64.1, 
P<O.OOl), and higher on the facet dependency on medica- 
tion or treatments (unequal variance t-value - 5.12, df 
62.9, PcO.001) than their matched healthy control subjects. 
Patients without symptoms scored significantly different 
from their control subjects on the domain environment 
(equal variance t-value - 2.95, df 52, P<O.Ol) and its facets 
home environment (equal variance t-value - 2.85, df 52, 
P=O.Ol) and transport (equal variance t-value - 2.75, df 
52, P~0.01). With respect to these latter areas, patients 
scored higher than the healthy persons. 
Regarding the other domains and facets, the results for 
symptomatic and asymptomatic patients were comparable. 
Therefore, the patients were treated as one group when 
their scores on these QOL domains and facets were 
compared with the matched healthy controls. 
754 R. M. WIRNSBERCER ET AL 
TABLE 4. Medical characteristics of the studied sarcoidosis 
patients with (group I) and without (group II) current 
symptoms 
Group I Group II 
(n=37) (n=27) 
Duration of disease, years* 4.455.1 6.1 & 5.9 
FEV, 
>80% 29 23 
60-80% 8 4 
DLCO 
>80% 22 24 
6Op80% 12 3 
40@60% 3t 
FEV, =forced expiration volume in 1 s; DLCO=diffusion 
capacity for carbon monoxide. 
*Data are expressed in mean + SD. tP<O.Ol group I vs. 
group II. 
Differences between the total sarcoidosis patient group 
and the total healthy control group, emerged on the domain 
physical health (unequal variance t-value 3.79, df 102.7, 
P<O.OOl) and its facets energy and fatigue (unequal vari- 
ance t-value 5.30, df 101, P<O-,001) and sleep and rest 
(unequal variance t-value 3.38, df 105.8, P=O.OOl). In 
general, the sarcoidosis group indicated that they felt 
physically less healthy and their general sense of QOL was 
lower. 
With respect to depressive symptoms, respondents with 
current symptoms had significantly higher BDI scores 
(9.8 & 7.8) than those without symptoms (4.3 f 5.6; 
unequal variances t-value - 3.27, df=61.79, PcO.01). Of 
the 64 patients, 12 (18%) had a BDI score of 15 or above 
(associated with significant depression) (5). Of those 12 
cases only one belonged to the group of patients without 
symptoms (group II). The average score on the CD1 was 
3.9 f 4.6. Univariate analysis still showed that symptomatic 
patients had higher CD1 scores (5.2 * 5.3) than those 
without symptoms (2.2 & 3.6; P<O.Ol). 
For the WHOQOL-100 only the domain psychological 
health and the facet fatigue were related to depression 
(PcO.01). No correlation between the facet fatigue and the 
domain psychological health was found. 
PULMONARY FUNCTION TESTS 
Pulmonary function tests of the respective patients groups 
are summarized in Table 4. No correlations between the 
WHOQOL-100 scores and the pulmonary function tests 
were found. 
Discussion 
The results of this study showed that the major problems of 
patients with sarcoidosis are fatigue and low levels of 
energy, and that these symptoms can be measured in a 
standardized format. 
Surprisingly, both patient groups - including patients 
who had reported no current symptoms ~ suffered from 
fatigue, sleeping problems and impaired general quality of 
life compared to the healthy control group. Sarcoidosis 
patients who had considered themselves asymptomatic also 
demonstrated an impaired QOL. 
A number of differences in QOL were found between the 
patient groups with and without current symptoms. Besides 
the physical problems mentioned above, patients with cur- 
rent symptoms suffered from impaired QOL mainly with 
respect to the level of independence. This area includes 
problems with patients’ mobility, working capacity, and 
activities of daily living. Moreover, group I had low levels 
of positive feelings and problems with recreation compared 
with group II. The fact that symptomatic sarcoidosis 
patients had a poor QOL compared to asymptomatic 
patients is not surprising. However, the areas in which QOL 
of these patients were impaired indicates that sarcoidosis 
has a considerable impact on daily life, even in patients with 
a relatively mild impairment of pulmonary function tests. 
Although in many disorders fatigue is a common prob- 
lem (lo), in sarcoidosis fatigue and loss of energy have had 
hardly any attention in the literature. In the present study, 
scores for fatigue and loss of energy were found to be 
similar to those of a patient population suffering from 
rheumatoid arthritis (20). 
Depressed mood and clinical depression are known to be 
associated with a lower QOL (3,5,18). In agreement with 
Klonoff et al., the sarcoidosis patients as a group did not 
meet the criteria for clinical depression (11). However, 
patients with current symptoms had higher BDI and CD1 
scores than asymptomatic patients. For the WHOQOL-100 
only the domain psychological health was associated with 
depression. This indicates that patients who were less 
satisfied with their psychological situation were more 
depressed. The facet fatigue was related to depression, but 
not to the domain psychological health. 
The association found between the psychological health 
of patients and depressive symptoms could be expected, 
irrespective of the impairment of sarcoidosis. The absence 
of an association between fatigue and psychological health, 
however, suggests that the relationship between fatigue and 
depression can be explained in the context of the ongoing 
sarcoidosis. Patients may become exhausted by the disease. 
Depressive symptoms, then, at least partly, are the 
psychological expression of exhaustion. 
For several years now, evidence has accumulated that 
patients with depressive disorders experience more limita- 
tions in well-being and social functioning, when compared 
with healthy controls and patients with chronic illness. The 
combination of chronic illness and depressive symptoms, 
however, is associated with increased morbidity and impair- 
ment of social functioning (21). Recent research suggests 
that functional ability plays a role here. In chronic obstruc- 
tive pulmonary disease (COPD), mood and attitude were 
found to be closely related to breathlessness (22). Kellner 
et al. found depressive symptoms to be associated with 
self-rated pulmonary complaints (i.e. breathlessness) (23). 
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COPD patients with greater distress and poorer coping had 
a higher probability of readmission to hospital independent 
of disease severity assessed by pulmonary function tests 
(24). In COPD, treating psychosocial aspects and improv- 
ing the patient’s ability to cope with the disease has been 
found to be an important aspect (6). In sarcoidosis, teach- 
ing patients to cope with the limitations implied by the 
disease, offering psychosocial support and treating depres- 
sive symptoms may also be important. Intervention 
research is needed to study the causal relationship between 
complaints and psychological factors. 
No relationship between pulmonary function tests and 
QOL was found. These results suggest that pulmonary 
function tests may not be sensitive parameters for QOL in 
sarcoidosis. Previously, we found that health status assessed 
by the Sickness Impact Profile (25) did not correlate with 
routinely performed pulmonary function tests in a sub- 
population of this patient group (26). Moreover, the 
majority of patients in the present study had a normal 
FEV, and DLCO. The limitations of this patient group, 
therefore, do not seem to be attributable to abnormalities in 
ventilatory mechanics. In our previous study mentioned 
above, we also found that respiratory muscle strength and 
endurance time was decreased in sarcoidosis patients com- 
pared to healthy controls. Moreover, a relationship was 
found between decreased respiratory muscle endurance 
time and the presence of symptoms such as fatigue (26). 
Future studies should focus on, in addition to respiratory 
symptoms, constitutional complaints such as fatigue and 
sleeping problems which are otherwise difficult to assess 
objectively. 
One limitation of this study was the rather low number of 
patients involved, which reduces the statistical power. 
In conclusion, this study shows that sarcoidosis, espe- 
cially in symptomatic patients, has a considerable impact 
on quality of life. Rather vague symptoms like fatigue and 
loss of energy as well as sleeping problems in patients with 
sarcoidosis can be assessed with the WHOQOL-100. More- 
over, the symptom fatigue was not associated with psycho- 
logical health and should be attributed to the ongoing 
disease. Psychological health was associated with depressive 
symptoms in sarcoidosis patients. Treating depressive 
symptoms and including psychological interventions in 
sarcoidosis patient care may improve QOL in these 
patients. Intervention research, however, is needed here. 
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